Statement: Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719  by IV.
Primary_evidence: INTERVENTION 1:    Zoledronic Acid 5 mg IV   Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).
Secondary_evidence: INTERVENTION 1:    Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1)   Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.   PI3K inhibitor BYL719: Given PO   Ado-trastuzumab emtansine: Given IV   Pharmacological study: Correlative studies   Laboratory biomarker analysis: Optional correlative studies INTERVENTION 2:    Cohort 1 (300mg BYL719, 3.6mg/kg T-DM1)   Patients receive 300 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.   PI3K inhibitor BYL719: Given PO   Ado-trastuzumab emtansine: Given IV   Pharmacological study: Correlative studies   Laboratory biomarker analysis: Optional correlative studies